Back to resultsExpression Profiling of microRNA Following Administration of Dexmedetomidine
Primary Purpose
Coronary Disease
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Dexmedetomidine Injection
Sponsored by
About this trial
This is an interventional basic science trial for Coronary Disease
Eligibility Criteria
Inclusion Criteria:
- The patients without arrithmia will undergo procedure.
Exclusion Criteria:
- The patients have bradycardia (hear rate is less than 60 beats per minute) or conduction block.
Sites / Locations
- Jinqiao Qian
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
before dexmedetomidine
Arm Description
We took blood samples before the administration of dexmedetomidine to determine exression level of microRNA in the subjects.
Outcomes
Primary Outcome Measures
microRNA differential expression
microRNA differential expression exerts cardioprotection effect on patients undergoing procedures.
Secondary Outcome Measures
Full Information
NCT ID
NCT03213743
First Posted
July 7, 2017
Last Updated
July 10, 2017
Sponsor
First Affiliated Hospital of Kunming Medical University
1. Study Identification
Unique Protocol Identification Number
NCT03213743
Brief Title
Expression Profiling of microRNA Following Administration of Dexmedetomidine
Official Title
Expression Profiling of microRNA Following Administration of Dexmedetomidine in Patients Undergoing Procedures
Study Type
Interventional
2. Study Status
Record Verification Date
July 2017
Overall Recruitment Status
Completed
Study Start Date
June 19, 2017 (Actual)
Primary Completion Date
June 21, 2017 (Actual)
Study Completion Date
June 21, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
First Affiliated Hospital of Kunming Medical University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the study is to find out the differential expression profiling of microRNA before and after adiministration of dexmedetomidine in patients undergoing procedures, and then investigators will do some in vitro studies to validate the functions of the microRNA.
Detailed Description
Background and objective: The use of dexmedetomidine may have benefits on the clinical outcomes of cardiac surgery. MicroRNAs are non-coding RNA sequences that act as regulators of gene expression. Investigators conduct a study to determine the role of microRNAs in cardioprotection mediated by dexmedetomidine.
Methods: In this study 3 patients were selected. The blood sample were taken before administration of dexmedetomidine.Investigators infused loading dose of dexmedetomidine for 10 minutes and maintaining dese of dexmedetomidine for 20 minutes.Thirty minutes after the administration, another blood samples were taken and stored in the liquid nitrogen and both the samples were marked. Those sample were analyzed for differentially expressed microRNA with Exiqon miRNA Array.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Disease
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
3 (Actual)
8. Arms, Groups, and Interventions
Arm Title
before dexmedetomidine
Arm Type
Other
Arm Description
We took blood samples before the administration of dexmedetomidine to determine exression level of microRNA in the subjects.
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine Injection
Other Intervention Name(s)
Dex group
Intervention Description
Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.
Primary Outcome Measure Information:
Title
microRNA differential expression
Description
microRNA differential expression exerts cardioprotection effect on patients undergoing procedures.
Time Frame
30 minutes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
The patients without arrithmia will undergo procedure.
Exclusion Criteria:
The patients have bradycardia (hear rate is less than 60 beats per minute) or conduction block.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jinqiao Qian, Ph.D
Organizational Affiliation
First Affiliated Hospital of Kunming Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jinqiao Qian
City
Kunming
State/Province
Yunnan
ZIP/Postal Code
650032
Country
China
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Expression Profiling of microRNA Following Administration of Dexmedetomidine
We'll reach out to this number within 24 hrs